Crain’s Health Pulse – January 18, 2017
Northwell Health has agreed to work with Germany-based oncology research company Indivumed to improve the quality of tissue specimens it procures from patients for precision cancer research. Through the three-year agreement, Indivumed will spend $5.9 million to fund a specialized team trained in the standard operating procedures the company uses to procure specimens around the world. The Feinstein Institute for Medical Research, part of Northwell Health, will hire and manage the team. Indivumed operates in Germany, Poland, India and the United States; Northwell Health is the fourth U.S. health system to work with Indivumed, and the partnership will give the health system access to the global cancer database. Having standard procedures across all the sites “facilitates discovery,” said Dr. James Crawford, senior vice president and executive director of laboratory services at Northwell. Northwell treats 19,000 cancer patients annually, and that patient volume was attractive to Indivumed, said Andrew Deubler, the company’s managing director. “The number and diversity of cancer patients and the commitment in their cancer program to clinical research is compelling,” he said. Northwell has operated a biobank for tissue specimens for the past 16 years. It’s one of a number of biobanks operated by academic medical centers in the New York City area but the first to work with Indivumed.